Sesen Bio News Releases http://ir.elevenbio.com/ Sesen Bio News Releases en Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-reports-first-quarter-2019-financial-results-and Company Announces Confirmed Meetings with the U.S. Food and Drug Administration in May and June 2019 to Review Registration Strategy for Vicinium ® Management to Host a Business Update Call Today at 8:00 a.m. EDT CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 13, 2019-- Sesen Bio (Nasdaq:SESN), a Mon, 13 May 2019 07:00:00 -0400 Sesen Bio News Releases 9716 Sesen Bio to Host Conference Call to Review First Quarter 2019 Financial Results and Updated Preliminary Data from Phase 3 VISTA Trial http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-host-conference-call-review-first-quarter-2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 13, Mon, 29 Apr 2019 07:30:00 -0400 Sesen Bio News Releases 9686 Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-reports-fourth-quarter-and-full-year-2018-financial Company Announces Additional Key Primary and Secondary Endpoints Further Supporting Vicinium ® Treatment Potential in High-Risk Non-Muscle Invasive Bladder Cancer Company on Track to Report Updated 12-Month Data from Phase 3 VISTA Trial of Vicinium in Mid-2019 Management to Host a Business Update Mon, 04 Mar 2019 07:30:00 -0500 Sesen Bio News Releases 9656 Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-host-conference-call-review-fourth-quarter-and-full CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that Company management will host a conference call and webcast on Monday, March 4, Mon, 25 Feb 2019 16:20:00 -0500 Sesen Bio News Releases 9631 Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-announces-positive-preliminary-12-month-data Complete Response Rates from All Four Time Points in Carcinoma in Situ Patients In-line with Phase 2 Data Company to Host Conference Call Today, January 3 , at 8:30 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company advancing Thu, 03 Jan 2019 06:30:00 -0500 Sesen Bio News Releases 9581 Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-host-conference-call-review-updated-vista-trial-data CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 27, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that company management will host a conference call on Thursday, Jan. Thu, 27 Dec 2018 06:30:00 -0500 Sesen Bio News Releases 9566 Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-appoints-drug-development-expert-dennis-kim-md-mph CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced the appointment of Dennis Kim , M.D., MPH, as chief medical officer. Mon, 03 Dec 2018 06:30:00 -0500 Sesen Bio News Releases 9536 Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-reports-third-quarter-2018-financial-results-and Company Expects to Report Six-Month Update from VISTA Trial in December 2018 ; On-Track to Report 12-Month VISTA Trial Data in Mid-2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics Thu, 08 Nov 2018 06:30:00 -0500 Sesen Bio News Releases 9521 Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018 http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-present-three-month-vista-trial-data-global-congress Biomarker Data Show that Molecular Target of Vicinium ™ , EpCAM, Expressed in Nearly All High-Grade NMIBC Patients CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today Thu, 20 Sep 2018 08:27:00 -0400 Sesen Bio News Releases 9501 Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-reports-second-quarter-2018-financial-results-and FDA Grants Fast Track Designation for Vicinium in NMIBC Company Focused on Defining Registration Pathway for Vicinium and Preparing for BLA Submission in 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 14, 2018-- Sesen Bio, Inc. (NASDAQ: SESN), a late-stage clinical company developing next-generation Tue, 14 Aug 2018 06:30:00 -0400 Sesen Bio News Releases 9481